2,4,5-三芳基-1H-吡唑-3(2H)-酮类化合物的合成与生物活性评价

目的 设计合成2,4,5-三芳基-1H-吡唑-3(2H)-酮类化合物,并研究其对ALK5信号通路、COX-1和COX-2信号通路的抑制活性,以期发现新型的ALK5或COX抑制剂。方法 关键中间体3-氧代-2,3-芳基丙酸甲酯（6）可以由两种方法制备：一是由芳基醛（1）与芳基乙酸甲酯（2）Aldol缩合后经Swern氧化的方法得到;二是通过芳基酰氯（5）与芳基乙酸甲酯的钠盐（4）直接缩合得到。化合物6与4-腈基苯肼（7）缩合得到4-（3,4-二芳基-5-氧代吡唑啉-1-基]）苯腈（8）,将化合物8的腈基水解为酰氨得到化合物（9）。应用基于细胞的TGF-Smad2检测评价化合物的ALK5抑制活性; 采用化学发光法测试化合物对COX1和COX2的抑制活性;采用MTT法检测化合物的细胞毒性。结果与结论 本文所合成的化合物和中间体均为新化合物,所有目标化合物和大部分中间体的结构经过了核磁与质谱的确证,其中目标化合物18个。多个化合物显示具有很好的对ALK5信号通路、COX信号通路的抑制活性,并且细胞毒性较小。     

1,5-二取代吡唑-3-甲酰胺类新化合物的合成及其生物活性

目的 设计合成新型1,5-二取代吡唑-3-甲酰胺类化合物,并对其抗ALK5活性进行初步评价.方法 以取代的苯乙酮及草酸二甲酯为原料,经多步反应合成目标化合物,用化学发光法检测报告基因表达产物萤火虫萤光素酶活性,计算化合物对ALK5的抑制率.结果与结论 共合成15个未见文献报道的新化合物,其结构经IR、1H-NMR和MS确证.初步生物活性评价结果显示化合物4g具有一定的抗ALK5活性.     

1，5-二芳基吡唑衍生物的合成及其对环氧合酶2的抑制活性

目的设计合成一系列1，5-二芳基吡唑衍生物，并考察其对环氧合酶2的抑制活性。方法以苯乙酮或对甲基苯乙酮为原料，经过缩合、环合、水解、还原、酯化等多步反应，得到1，5-二芳基．3-取代吡唑衍生物。结果与结论共合成了10个中间体和10个目标化合物，其中，18个化合物（8个中间体和10个目标化合物）是未见文献报道的新化合物，其结构经MS和^1H-NMR确证。所有目标化合物均具有一定的环氧合酶2抑制活性，其中化合物1i的抑制率为31．77％。     

多取代三氮唑类化合物的合成及其抗肿瘤活性研究

目的设计合成一系列4-胺甲酰-1,5-双芳基-1,2,3-三氮唑类化合物,并评价其抗肿瘤活性。方法以叠氮化钠为原料,经亲核取代反应制成有机叠氮化物后与丙炔酸甲酯通过Huisgen 1,3-偶极环加成反应得到5-碘代-1,2,3-三氮唑,再与单质硫和苄溴类化合物经3步连续反应"一锅法"得到1-对甲氧基苄基-4-甲氧甲酰-5-苄基硫醚-1,2,3-三氮唑,对三氮唑环上的4-甲氧甲酰基进行胺解反应得到目标化合物。采用MTT法测定目标化合物对人乳腺癌细胞(MCF-7)、肝癌细胞(Hep G2)、肺癌细胞(A549)和宫颈癌细胞(He La)的抑制活性。结果与结论合成了15个未见报道的4-胺甲酰-1,5-双芳基-1,2,3-三氮唑类化合物,其结构经1H-NMR、13C-NMR及HR-MS谱确证。其中,化合物7a对Hep G2、A549和He La细胞均表现出中等程度的抑制活性(IC50值分别为23.00、33.88、26.66μmol·L-1),有进一步研究的价值。     

新型ALK和c-Met激酶抑制剂的合成及抗肿瘤活性

目的设计合成一系列新型ALK和c-Met激酶抑制剂,并测定其抗肿瘤细胞增殖活性。方法以上市的ALK和c-Met激酶抑制剂克里唑替尼(crizotinib)为先导化合物,设计并合成了含1,2,3-三氮唑的吡嗪类化合物。采用Alarm Blue方法测试了目标化合物对人神经母细胞瘤细胞株(SH-SY5Y)以及人胃癌细胞(SNU-5)的抗增殖活性。结果与结论合成了8个未见文献报道的新化合物,其结构经~1H-NMR、~(13)C-NMR、MS谱确证。初步体外活性评价结果表明,目标化合物对人神经母细胞瘤、人胃癌细胞均具有抑制活性,其中化合物7a对SH-SY5Y抑制活性最高,与阳性对照药克里唑替尼相当;化合物7a~7e对SNU-5的抑制活性略低于阳性对照药,但其IC_(50)值比较理想,此系列化合物可能具有潜在的抗肿瘤活性。     

4-氨基嘧啶取代的双芳基脲类化合物的合成及抗肿瘤细胞增殖活性

目的设计并合成含有不同取代苯环结构的双芳基脲类化合物,初步评价其体外抗肿瘤细胞增殖活性。方法以ABT-869为先导化合物,利用生物电子等排原理,将其3-氨基-1H-吲唑结构改造为氨基嘧啶环设计新目标化合物;以对硝基苯乙腈为起始原料,经与N,N-二甲基甲酰胺二甲缩醛(DMF-DMA)缩合、环合、还原、酰化、成脲共5步反应合成目标化合物;以索拉非尼(sorafenib)为阳性对照药,采用MTT法,测试目标化合物对乳腺癌细胞株MDA-MB-231的抗增殖活性。结果与结论合成了18个未见报道的双芳基脲类化合物,其结构经1H-NMR和MS谱确证;6个化合物显示较好的体外活性,其中,化合物5r活性突出,为对照药索拉非尼的1.8倍;并且初步探讨了目标化合物的构效关系。     

吡唑并[1，5-α]嘧啶类化合物的合成及其抗肿瘤活性

目的设计合成新的吡唑并[1,5-a]嘧啶类化合物,并评价其抗肿瘤活性。方法根据吡唑并[1,5-a]嘧啶类抗肿瘤药物的基本结构设计了一系列5-胺甲基-7-苯胺基吡唑并[1,5-a]嘧啶类化合物,并以丙二腈和原甲酸三乙酯为起始原料,经5步反应得到目标产物。采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行评价。结果与结论合成了11个未见文献报道的化合物,结构经质谱和核磁共振氢谱确证。化合物6显示出很好的抗肿瘤活性。     

含吡咯结构的二芳氨基嘧啶类ALK抑制剂的设计合成及抗肿瘤活性研究

目的设计并合成结构新颖的含吡咯结构的二芳氨基嘧啶类ALK抑制剂。方法基于色瑞替尼与ALK蛋白的共晶模型及其构效关系,设计含吡咯结构的二芳氨基嘧啶类化合物;以2,4,5-三氯嘧啶和5-氟-2-硝基苯甲醚为主要起始原料,经N-烃化、N-酰化、N-烃化、硝基还原和N-烃化5步反应得到目标化合物I1;I1与多种脂肪胺经Mannich反应得到目标化合物I2～I16。采用MTT法及HTRF激酶测试法,评价目标化合物的体外抗肿瘤活性。结果与结论合成了16个未见文献报道的二芳氨基嘧啶类化合物,其结构经MS、~1H-NM R谱确证;大部分化合物显示出较强的活性,其中化合物I4的活性最佳,其抑制人间变性淋巴瘤细胞Karpas299和人肺腺癌细胞H2228的IC50值分别为0. 021、0. 12μmol·L~(-1),化合物I4抑制ALK激酶的IC50值为8. 7 nmol·L~(-1),与色瑞替尼活性相当,有进一步研究的价值。     

吡唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性

目的 设计合成新的吡唑并[1,5-a]嘧啶类化合物,并评价其抗肿瘤活性.方法 根据吡唑并[1,5-a]嘧啶类抗肿瘤药物的基本结构设计了一系列5-胺甲基-7-苯胺基吡唑并[1,5-a]嘧啶类化合物,并以丙二腈和原甲酸三乙酯为起始原料,经5步反应得到目标产物.采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行评价.结果与结论 合成了11个未见文献报道的化合物,结构经质谱和核磁共振氢谱确证.化合物6显示出很好的抗肿瘤活性.     

3,4-二氢-4-芳基香豆素类化合物的合成及其生物活性研究

目的 设计合成一系列3,4-二氢4-芳基香豆素类化合物,并评价其抗氧化、抗肿瘤活性.方法 以取代苯甲醛为原料,经缩合及Ponndorf反应制得目标化合物.采用DPPH法测定目标化合物的抗氧化活性;采用MTT法以胃癌细胞BGC-823为测试细胞株对目标化合物进行体外抗肿瘤活性评价.结果 与结论合成了10个新的3,4-二氢...     

Potent in vitro and in vivo antitubercular activity of certain newly synthesized indophenazine 1,3,5-trisubstituted pyrazoline derivatives bearing benzofuran

Fourteen newly synthesized derivatives of indophenazine 1,3,5-trisubstituted pyrazoline bearing benzofuran were prepared from benzofuran chalcones with indophenazine hydrazide through cycloaddition reaction. All the compounds were screened for their in vitro and in vivo antitubercular activity against drug resistant and multidrug-resistant Mycobacterium tuberculosis H₃₇RV. The MIC₅₀ and MIC₉₀ were estimated and compared with rifampicin and gatifloxacin standard drugs. Nitro group containing at ortho 5j, meta 5e, furan ring containing 5m and ortho 5i, para 5h chloro containing compounds were exhibited significant in vitro, in vivo antitubercular activity against standard drugs.     

Synthesis and antimycobacterial activity of novel 4-[5-(substituted phenyl)-1-phenyl-4,5-dihydro-1<Emphasis Type="Italic">H</Emphasis>-3-pyrazolyl]-2-methylphenol derivatives

In the present investigation, 4-hydroxy-3-methylacetophenone, on condensation with appropriate aldehydes in methanolic potassium hydroxide solution, yielded the corresponding chalcones (C_I-XI). These corresponding chalcones were reacted with phenyl hydrazide in glacial acetic acid, which led to the formation of novel 4-[5-(substituted phenyl)-1-phenyl-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol derivatives. All newly synthesized compounds were evaluated for their antimycobacterial activities against isoniazid-resistant Mycobacterium tuberculosis using agar dilution. 4-[5-(4-Fluoro phenyl)-1-phenyl-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol showed good antimycobacterial activity, with a minimum inhibitory concentration of 0.62 μg/ml.     

Synthesis of 1-substituted 3-aryl-5-aryl(hetaryl)-2-pyrazolines and study of their antitumor activity

Three series of novel 1,3,5-trisubstituted 2-pyrazoline derivatives containing thiophene and benzodioxol moieties as potential antitumor agents were synthesized. The in vitro antitumor activity of the obtained compounds was determined at the National Cancer Institute (NCI). The 5-(benzo[d][1,3]dioxol-5-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (9a) is the most prominent of the compounds due to its remarkable activity toward leukemia (RPMI-8226), renal cancer (UO-31) and prostate cancer (DU-145) cell lines with GI(50) values of 1.88, 1.91 and 1.94 μM, respectively.     

Synthesis and Antibacterial and Antifungal Studies of Novel Nitrogen Containing Heterocycles from 5-Ethylpyridin-2-ethanol

A novel series of chalcones, pyrimidines and imidazolinone is described; chalcones (4a-o) were prepared from the lead molecule 4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde. Pyrimidine (5a-o) derivatives were prepared from the reaction of chalcones and guanidine nitrate in alkali media. Imidazolinones (6a-o) were synthesized from reaction of pyrimidine and oxazolone derivatives (prepared by Erlenmeyer azlactone synthesis). The structures of the synthesized compounds were assigned on the basis of elemental analysis, IR, (1)H and (13)C NMR spectral data. All the products were screened against different strains of bacteria and fungi. Most of these compounds showed better inhibitory activity in comparison to the standard drugs.     

Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities

A new series of 2,4-dianilino-5-fluoropyrimidine derivatives were designed and synthesized and their anaplastic lymphoma kinase (ALK) inhibitory activities were evaluated by biochemical and cell-based assays in order to discover a new ALK inhibitor. Most compounds synthesized showed good inhibitory activities against ALK and good cytotoxic activities in H3122 cell line. The best compound 6f showed good activity against wild-type ALK along with crizotinib-resistant mutant ALK, and it showed 6 times better activity in cell-based assay than crizotinib. Some SAR studies were performed by the comparisons of the activities between 6 and the designed-synthesized compounds.     

磺胺噻二嗪硫酮衍生物的合成及其抑菌活性

利用药物化学骈合原理设计并合成了一系列新的３，５－二取代１，３，５－噻二嗪－２－硫酮类化合物，其结构经红外光谱，紫外光谱及元素分析证实，抑菌活性试验显示了良好的抑菌活性。     

Synthesis and evaluation of 2,4,6-trisubstituted pyrimidine derivatives as novel antileishmanial agents

A series of new 2,4,6-trisubstituted pyrimidine derivatives 8(a–j) were synthesized by reacting substituted chalcones containing imidazole 6(a–d) and benzimidazole 7(a–f) with guanidine hydrochloride in the presence of strong base. Substituted chalcones were synthesized by reacting 4-(1H-imidazol-1-yl)benzaldehyde or 4-(1H-benzo[d]imidazol-1-yl)benzaldehyde with different substituted acetophenones in the presence of 40 % NaOH in methanol. The synthesized compounds were confirmed by IR, ¹HNMR, and mass spectral data and screened for antileishmanial activity. Antileishmanial activity was performed against Leishmania donovani parasite, and percentage lysis inhibition were calculated by meglumine antimoliate taking a positive control and chloroform (0.1 % CHCl₃) treatment served as control. Among all the compounds, 8h and 8j exhibited 50–57 % inhibition against promastigotes, thus providing new structural lead for antileishmanials.     

Novel chalcones and 1,3,5-triphenyl-2-pyrazoline derivatives as antibacterial agents

Novel sixteen chalcones and thirteen 1,3,5-triphenyl-2-pyrazolines were synthesized and characterized using FT-IR, HR-Mass, NMR (1H-NMR, 13C-NMR, 135 DEPT, 1H-1H CoSY and 1H and 13C CoSY) and XRD. These compounds were evaluated for their antibacterial activity against six micro-organisms, namely Bacillus subtilis NCIM 2718, Staphylococcus aureus NCIM 5021, Salmonella typhi NCIM 2501, Enterobacter aerogenes NCIM 5139, Pseudomonas aeruginosa NCIM 5029, and Proteus vulgaris NCIM 2813 by twofold dilution method using resazurin as the indicator dye. In the case of chalcones, compounds with hydroxyl and bromo substitutions in the B-ring favor activity and benzyloxy substitution irrespective of its position in the A-ring. In the case of 1,3,5-triphenyl-2-pyrazolines, chloro substitution in the A-ring favors activity. Hydrophilic/lipophilic balance of the compounds plays a major role in their antibacterial activity.